Editas Medicine, Inc. (NASDAQ:EDIT) insider Katrine Bosley sold 8,333 shares of the company’s stock in a transaction that occurred on Wednesday, November 1st. The shares were sold at an average price of $23.64, for a total value of $196,992.12. Following the completion of the sale, the insider now directly owns 1,393,322 shares in the company, valued at approximately $32,938,132.08. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Katrine Bosley also recently made the following trade(s):

  • On Monday, October 2nd, Katrine Bosley sold 8,333 shares of Editas Medicine stock. The stock was sold at an average price of $24.78, for a total value of $206,491.74.
  • On Friday, September 1st, Katrine Bosley sold 10,000 shares of Editas Medicine stock. The stock was sold at an average price of $20.42, for a total value of $204,200.00.
  • On Tuesday, September 5th, Katrine Bosley sold 16,666 shares of Editas Medicine stock. The stock was sold at an average price of $20.33, for a total value of $338,819.78.
  • On Friday, August 11th, Katrine Bosley sold 16,666 shares of Editas Medicine stock. The stock was sold at an average price of $20.02, for a total value of $333,653.32.

Shares of Editas Medicine, Inc. (EDIT) traded up $1.00 on Friday, hitting $24.93. The company had a trading volume of 998,668 shares, compared to its average volume of 1,140,000. The company has a debt-to-equity ratio of 0.18, a quick ratio of 6.74 and a current ratio of 6.74. Editas Medicine, Inc. has a twelve month low of $12.46 and a twelve month high of $29.20.

Editas Medicine (NASDAQ:EDIT) last issued its earnings results on Wednesday, August 9th. The company reported ($0.65) earnings per share for the quarter, missing the consensus estimate of ($0.64) by ($0.01). The firm had revenue of $3.10 million during the quarter, compared to analysts’ expectations of $2.20 million. Editas Medicine had a negative return on equity of 67.75% and a negative net margin of 2,091.36%. The company’s quarterly revenue was down 8.8% compared to the same quarter last year. During the same period last year, the business posted ($0.54) earnings per share. equities research analysts expect that Editas Medicine, Inc. will post -2.88 EPS for the current year.

COPYRIGHT VIOLATION NOTICE: This story was first posted by Watch List News and is owned by of Watch List News. If you are viewing this story on another site, it was stolen and republished in violation of U.S. and international trademark and copyright legislation. The original version of this story can be read at https://www.watchlistnews.com/editas-medicine-inc-edit-insider-katrine-bosley-sells-8333-shares-of-stock/1678815.html.

A number of research analysts have weighed in on EDIT shares. ValuEngine lowered Editas Medicine from a “hold” rating to a “sell” rating in a research note on Wednesday, October 25th. Zacks Investment Research lowered Editas Medicine from a “hold” rating to a “sell” rating in a research note on Tuesday, October 10th. Cann started coverage on Editas Medicine in a research note on Monday, July 17th. They set a “market perform” rating on the stock. J P Morgan Chase & Co set a $27.00 price target on Editas Medicine and gave the stock a “hold” rating in a research note on Wednesday, August 9th. Finally, Morgan Stanley reissued an “equal weight” rating and set a $28.00 price target (up previously from $27.00) on shares of Editas Medicine in a research note on Friday, October 6th. One equities research analyst has rated the stock with a sell rating, six have given a hold rating, four have issued a buy rating and one has given a strong buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $25.88.

Institutional investors and hedge funds have recently modified their holdings of the stock. IHT Wealth Management LLC purchased a new position in shares of Editas Medicine in the 2nd quarter worth $107,000. Bank of America Corp DE raised its position in shares of Editas Medicine by 72.2% in the 1st quarter. Bank of America Corp DE now owns 5,936 shares of the company’s stock worth $133,000 after buying an additional 2,489 shares during the period. DekaBank Deutsche Girozentrale purchased a new position in shares of Editas Medicine in the 2nd quarter worth $127,000. Legal & General Group Plc raised its position in shares of Editas Medicine by 308.4% in the 2nd quarter. Legal & General Group Plc now owns 8,654 shares of the company’s stock worth $145,000 after buying an additional 6,535 shares during the period. Finally, Creative Planning raised its position in shares of Editas Medicine by 8,910.9% in the 2nd quarter. Creative Planning now owns 9,101 shares of the company’s stock worth $153,000 after buying an additional 9,000 shares during the period. 70.45% of the stock is currently owned by institutional investors and hedge funds.

Editas Medicine Company Profile

Editas Medicine, Inc is a genome editing company. It is engaged in treating patients with genetically defined diseases by correcting their disease-causing genes. It operates through developing and commercializing genome editing technology segment. It is developing a genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR) technology.

Insider Buying and Selling by Quarter for Editas Medicine (NASDAQ:EDIT)

Receive News & Ratings for Editas Medicine Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Editas Medicine Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.